UPFRONT OVERALL SURVIVAL MODELLING IN COMPARISON TO REAL WORLD DATA: LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS IN SOUTH KOREA

被引：0
|
作者：
Felix, J. [1 ]
Vandewalle, B. [1 ]
Almeida, J. [1 ]
Valeska, A. [1 ]
机构：
[1] Exigo Consultores, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.073
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM20
引用
收藏
页码：A729 / A729
页数：1
相关论文
共 50 条
  • [31] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    BLOOD, 2007, 110 (11) : 128A - 128A
  • [32] The Association of Globulin Level with Treatment Response and Overall Survival in Patients with Multiple Myeloma
    Eren, Rafet
    Ozdemir, Ozlem
    Aslan, Ceyda
    Dogu, Mehmet Hilmi
    Altindal, Sermin
    Yokus, Osman
    Suyani, Elif
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2018, 2 (02): : 61 - 64
  • [33] Augmentation of Real-World Mortality Data in the Electronic Medical Record: Assessing the Impact on Overall Survival Estimates in Multiple Myeloma
    Liu, Pei
    Lan, Ziyu
    Walker, Brigham
    Ray, Herman E.
    Smith, Helen
    BLOOD, 2023, 142
  • [34] Real-World Insights: Treatment Patterns and Overall Survival in Patients with Small-Cell Lung Cancer in South Korea a Single Center Experience
    Park, S.
    Kang, D.
    Lee, H.
    Lim, H.
    Cho, J.
    Ahn, M. -J.
    Kim, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S663 - S664
  • [35] Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
    Dos Santos, David M. Cordas
    Saliba, Rima M.
    Patel, Romil
    Bashir, Qaiser
    Saini, Neeraj
    Hosing, Chitra
    Kebriaei, Partow
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday
    Ahmed, Haris
    Lee, Hans C.
    Manasanch, Elisabet E.
    Patel, Krina K.
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (06) : 1077 - 1083
  • [36] Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
    Mian, Hira
    LeBlanc, Richard
    Louzada, Martha
    Masih-Khan, Esther
    McCurdy, Arleigh
    Venner, Christopher P.
    Stakiw, Julie
    Kardjadj, Moustafa
    Jimenez-Zepeda, Victor H.
    Sebag, Michael
    White, Darrell
    Aslam, Muhammad
    Song, Kevin
    Reiman, Anthony
    Kotb, Rami
    Gul, Engin
    Reece, Donna
    CANCER MEDICINE, 2023, 12 (04): : 4357 - 4362
  • [37] The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data
    Cherniawsky, Hannah
    Sandhu, Irwindeep
    Chu, Michael P.
    Hewitt, Joanne D.
    Ismail, Ismail
    Belch, Andrew
    Pilarski, Linda M.
    Nikitina, Tatiana
    Venner, Christopher P.
    BLOOD, 2017, 130
  • [38] Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
    Leleu, Xavier
    Katodritou, Eirini
    Kuehr, Thomas
    Terpos, Evangelos
    Caers, Jo
    Zambello, Renato
    Brescianini, Alessandra
    Liang, Tony
    Wetten, Sally
    Badelita, Sorina N.
    EJHAEM, 2023, 4 (01): : 174 - 183
  • [39] LONGER DURATION OF TREATMENT AND MAINTENANCE OF BEST RESPONSE WITH LENALIDOMIDE plus DEXAMETHASONE INCREASES OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Dimopoulos, M.
    Bravo, M. -L.
    Weber, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 382 - 382
  • [40] Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
    Xu, Jingyu
    Yan, Wenqiang
    Fan, Huishou
    Liu, Jiahui
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S159 - S159
12345